Intercepting Blood Cancers

14 - 16 March, 2024

Lisbon, Portugal

The 2024 Intercepting Blood Cancers Workshop (IBC) will provide a unique, interactive platform for presentations on key clinical trial data and expert clinical insights for early interventions in blood cancers and how this impacts outcomes for patients; three key topic tracks will include:

  • Monoclonal B lymphocytosis (MBL), chronic lymphocytic leukemia (CLL) and low-grade lymphoma
  • Myelodysplastic syndromes (MDS), clonal hematopoiesis of indeterminate potential (CHIP) and acute myeloid leukemia (AML)
  • Multiple myeloma (MM), smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS)
The current aims of the workshop are to:
  • Describe current knowledge of blood cancer precursors and how these might enable early clinical intervention
  • Discuss ongoing clinical studies and any available data from these on treatment interceptions for early-stage blood cancers
  • Share knowledge and clinical insights between blood cancer disciplines and therapy areas
  • Plan for publication and dissemination of consensus findings from discussions across each of the key topic tracks
striped logostriped logooutlined logo

Supporter Opportunities

If you are interested in becoming a supporter of the IBC Workshop, please contact us

striped circlestriped circlestriped circlestriped logo

The IBC 2023 Workshop was supported by:

Gold Supporters

Silver Supporters